Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds
about
Burden of gastrointestinal cancers and problem of the incomplete information; how to make up the data?Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunitiesOligodendroglioma: pathology, molecular mechanisms and markersThe MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomideResearch funding for addressing tobacco-related disease: an analysis of UK investment between 2008 and 2012Investments in cancer research awarded to UK institutions and the global burden of cancer 2000-2013: a systematic analysis.Bayesian adjustment of gastric cancer mortality rate in the presence of misclassificationBayesian correction for mortality trend of oral cavity cancer.Mortality trends of gastrointestinal cancers in Iranian population.Redox regulation of methionine aminopeptidase 2 activityEstimation of savings of life-years and cost from early detection of cervical cancer: a follow-up study using nationwide databases for the period 2002-2009.The burden of premature mortality in Spain using standard expected years of life lost: a population-based studyLeukemia cancer mortality trend in iran, from 1995 to 2004Years of life lost as a measure of cancer burden on a national levelBiology, genetics and imaging of glial cell tumoursCombination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding.Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic reviewIntracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motilityDeltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survivalAre the Norwegian health research investments in line with the disease burden?Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.Using Health Care Utilization and Publication Patterns to Characterize the Research Portfolio and to Plan Future Research Investments.Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiformeCosts and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009The loss in expectation of life after colon cancer: a population-based studySomatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomideLung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study.NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice.The Productivity Costs of Premature Mortality Due to Cancer in Australia: Evidence from a Microsimulation Model.Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedemaAn analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States values.Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.Years of Life Lost and Childhood and Adolescent Cancer Mortality in Yazd Province, Iran (2004-2009).Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.Research output and the public health burden of cancer: is there any relationship?
P2860
Q26770163-16E2BEA6-DBDD-4357-ABBF-4C40C1FF4253Q26799013-C476B5F6-E0C0-4F3A-A4A6-58987A5F822AQ27002448-874A6C6C-6DB3-40DA-A156-B90D3837CE3FQ27853156-B6C7954C-C1B7-4FB8-BAF3-90FF0282FECFQ28596195-26378E54-C297-47A3-812F-5D99609A0B26Q30491468-F84D60AB-2533-4F56-B49E-00EFACA2730CQ33560101-7D8363F9-5252-49F0-B7E3-44CBFB1073E3Q33596506-537D233F-037E-4D42-A786-0E0E60750B68Q33596740-4D14A509-AB5A-43EE-BE14-951DDCDBAB0AQ33652216-42B6868A-B056-4038-899C-D109C3C2C3D0Q33922007-4AEADE23-612D-44D1-B855-16AD090F7B4AQ34046757-76BBBD2D-6BB6-4334-8A59-ED03FE3E8D85Q34082410-16009E85-1794-41E1-9FE0-23526A5416EDQ34113539-229D63BF-C382-48DA-BB30-E32046BB2D8AQ34203979-19F1FB2D-6BB9-4921-8164-306A9FFEDDB1Q34253705-6A209C06-940E-4110-9B18-037DFADA9A70Q34338677-3A2EEF19-E119-4641-9F6C-D41EF2BE78D3Q34383339-81EADBEC-8491-4285-A404-43F490B1F71DQ34390108-5F3A247E-A5E6-4EFC-9F93-AB8461EAF183Q34483732-D209829D-F84D-488A-AC56-155CAE6E30B4Q34603835-6ABECE35-6DE0-4CD6-AB88-79BF6D06EE0DQ34636332-72257F39-0C7C-4A7B-B612-C9FD0CF6AA14Q34672618-E89D9952-E827-46CD-BE3A-CF2E33E2950FQ34673111-E17C15A7-140D-432B-837F-9C75EA5C59C7Q35034698-3C9D0501-C220-4110-A1B9-26A5BCE29A09Q35106644-32A7F533-B17E-40CD-A1CA-DB7307EEEA75Q35469475-2171CA06-71B1-4802-9A18-3A7443C10BC2Q35633808-752EC101-5FA1-470B-B1D2-FD49EB8601FCQ35741879-851FD847-ABA7-4A9C-9363-65EA57947BEBQ35781382-2A5384DF-4B95-4B35-A518-6A735A3B8C23Q35836657-A1D09E6E-46B0-4865-8029-8BD2CDAA94B2Q36204670-62BCFCBC-7A20-4028-9B5E-ADC97CEC7778Q36220159-F29D8BCB-300D-494E-B131-7A2C5B2CF61DQ36223878-0F84A8AA-FBB3-4507-9970-B23E7AA2C134Q36238146-B7E2A2A1-AD87-4930-833F-11C03E86FC1BQ36367436-87E47655-40DC-48C4-A68D-F055F910DC25Q36397078-ADCB3FBA-B973-4010-9AD0-8A4C370B1788Q36673354-CF6C7BF2-C1FB-4073-A0ED-A24F9E25B1B4Q36755432-5B9EA317-4C60-4D53-ADD4-585D119E90D5Q36807924-200F8831-71DD-49C0-853B-375AE34061A2
P2860
Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Years of life lost (YLL) from ...... when allocating research funds
@ast
Years of life lost (YLL) from ...... when allocating research funds
@en
Years of life lost (YLL) from ...... when allocating research funds
@nl
type
label
Years of life lost (YLL) from ...... when allocating research funds
@ast
Years of life lost (YLL) from ...... when allocating research funds
@en
Years of life lost (YLL) from ...... when allocating research funds
@nl
prefLabel
Years of life lost (YLL) from ...... when allocating research funds
@ast
Years of life lost (YLL) from ...... when allocating research funds
@en
Years of life lost (YLL) from ...... when allocating research funds
@nl
P2093
P3181
P356
P1476
Years of life lost (YLL) from ...... when allocating research funds
@en
P2093
F P Treasure
N G Burnet
R J Benson
S J Jefferies
P2860
P2888
P3181
P356
10.1038/SJ.BJC.6602321
P407
P577
2005-01-31T00:00:00Z
P5875
P6179
1007735948